Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 2
1981 1
1982 1
1983 1
1984 2
1985 2
1986 2
1987 1
1988 1
1995 1
1996 2
1997 1
1998 2
2000 1
2001 1
2002 1
2003 1
2004 2
2006 4
2008 5
2009 4
2010 10
2011 8
2012 5
2013 2
2014 5
2015 2
2016 2
2018 1
2019 1
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Brautbar A, Covarrubias D, Belmont J, Lara-Garduno F, Virani SS, Jones PH, Leal SM, Ballantyne CM. Brautbar A, et al. Atherosclerosis. 2011 Dec;219(2):737-42. doi: 10.1016/j.atherosclerosis.2011.08.015. Epub 2011 Aug 22. Atherosclerosis. 2011. PMID: 21889769 Free PMC article. Clinical Trial.
We sought to identify single nucleotide polymorphisms (SNPs) associated with HDL-C, TG, and apolipoprotein A1 (ApoA-I) response to combination therapy with statins and fenofibric acid (FA) in individuals with atherogenic dyslipidemia. METHODS: 2228 individuals with …
We sought to identify single nucleotide polymorphisms (SNPs) associated with HDL-C, TG, and apolipoprotein A1 (ApoA-I) response to combinati …
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Jones PH, Bays HE, Davidson MH, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Jones PH, et al. Clin Drug Investig. 2008;28(10):625-34. doi: 10.2165/00044011-200828100-00003. Clin Drug Investig. 2008. PMID: 18783301 Clinical Trial.
A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new formulation of fenofibric acid. METHODS: Three separate 22-week, phase III, double-blind, active-controlled trials will evalu …
A comprehensive, controlled clinical trial programme was thus designed to evaluate three separate statins in combination with ABT-335, a new …
Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR, Digiacinto J, Davis MW. Godfrey AR, et al. Clin Ther. 2011 Jun;33(6):766-75. doi: 10.1016/j.clinthera.2011.05.047. Clin Ther. 2011. PMID: 21704241 Clinical Trial.
Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety. A new orally administered agent, fenofibric acid, was developed as an alternative to fenofibrate. ...Fenofibric acid at the dose stu …
Fenofibrate is a prodrug that is rapidly and completely hydrolyzed to fenofibric acid, the active moiety. A new orally adminis …
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Martin PD, Dane AL, Schneck DW, Warwick MJ. Martin PD, et al. Clin Ther. 2003 Feb;25(2):459-71. doi: 10.1016/s0149-2918(03)80089-9. Clin Ther. 2003. PMID: 12749507 Clinical Trial.
The steady-state pharmacokinetics of rosuvastatin and fenofibric acid, both as substrate and as interacting drug, were investigated on day 7 of dosing. ...CONCLUSION: Coadministration of rosuvastatin and fenofibrate produced minimal changes in rosuvastatin and fe …
The steady-state pharmacokinetics of rosuvastatin and fenofibric acid, both as substrate and as interacting drug, were investi …
Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.
Zhu T, Ansquer JC, Kelly MT, Sleep DJ, Pradhan RS. Zhu T, et al. J Clin Pharmacol. 2010 Aug;50(8):914-21. doi: 10.1177/0091270009354995. Epub 2010 Feb 9. J Clin Pharmacol. 2010. PMID: 20145261 Clinical Trial.
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and fenofibrate (which is converted to fenofibric acid in vivo) in healthy volunteers. ...Serial blood samples were collected for 1 …
This study compared the gastrointestinal (GI) absorption characteristics and absolute bioavailability of fenofibric acid and f …
Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.
Roth EM, McKenney JM, Kelly MT, Setze CM, Carlson DM, Gold A, Stolzenbach JC, Williams LA, Jones PH. Roth EM, et al. Am J Cardiovasc Drugs. 2010;10(3):175-86. doi: 10.2165/11533430-000000000-00000. Am J Cardiovasc Drugs. 2010. PMID: 20524719 Clinical Trial.
Primary and secondary variables were mean percent changes in LDL-C comparing rosuvastatin/fenofibric acid 20 mg/135 mg with simvastatin 40 mg and rosuvastatin/fenofibric acid 10 mg/135 mg and rosuvastatin/fenofibric acid 5 mg/135 mg with …
Primary and secondary variables were mean percent changes in LDL-C comparing rosuvastatin/fenofibric acid 20 mg/135 mg with si …
Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Davidson M, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Setze C, Carlson DM, Stolzenbach J. Davidson M, et al. Cardiovasc Drugs Ther. 2012 Aug;26(4):349-58. doi: 10.1007/s10557-012-6395-z. Cardiovasc Drugs Ther. 2012. PMID: 22622962 Free PMC article. Clinical Trial.
PURPOSE: Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk and can be effectively treated with fenofibric acid. A trial is under way to evaluate the effect of once-daily fenofibric …
PURPOSE: Elevated triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels contribute to cardiovascular disease risk a …
LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
Brautbar A, Virani SS, Belmont J, Nambi V, Jones PH, Ballantyne CM. Brautbar A, et al. J Lipid Res. 2012 Mar;53(3):556-560. doi: 10.1194/jlr.M020404. Epub 2012 Jan 11. J Lipid Res. 2012. PMID: 22236405 Free PMC article. Clinical Trial.
We sought to identify single nucleotide polymorphisms (SNPs) associated with apoC-III level response to combination therapy with statins and fenofibric acid (FA) in individuals with mixed dyslipidemia. Participants (n = 1,250) in a multicenter, randomized, double-bl …
We sought to identify single nucleotide polymorphisms (SNPs) associated with apoC-III level response to combination therapy with statins and …
Pharmacokinetics and Safety of Fenofibrate in Participants with Mild Hepatic Impairment or with Advanced Fibrosis due to Metabolic-Associated Fatty Liver Disease.
Younis IR, Weber EJ, Nelson C, Qin AR, Watkins TR, Othman AA. Younis IR, et al. J Clin Pharmacol. 2025 Jul;65(7):850-859. doi: 10.1002/jcph.70005. Epub 2025 Mar 7. J Clin Pharmacol. 2025. PMID: 40052566 Free PMC article. Clinical Trial.
In the phase 1 study, the AUC(inf) of fenofibric acid was 25% higher in participants with mild hepatic impairment than in healthy matched participants. ...Fenofibrate was well tolerated, and modest differences were observed in fenofibric acid exposure …
In the phase 1 study, the AUC(inf) of fenofibric acid was 25% higher in participants with mild hepatic impairment than in heal …
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC. Kipnes MS, et al. Clin Drug Investig. 2010;30(1):51-61. doi: 10.2165/11319800-000000000-00000. Clin Drug Investig. 2010. PMID: 19995098 Clinical Trial.
Treatment was once-daily oral coadministration of fenofibric acid 135 mg and moderate-dose statin (rosuvastatin 20 mg, simvastatin 40 mg or atorvastatin 40 mg), and was identical to the treatment received in the year 1 study. ...Rhabdomyolysis was not reported in an …
Treatment was once-daily oral coadministration of fenofibric acid 135 mg and moderate-dose statin (rosuvastatin 20 mg, simvast …
70 results